Opinion

Video

Final Thoughts

Author(s):

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA,Amir Ali, PharmD, BCOP

The panel discussion concludes with final thoughts on the future landscape of newly diagnosed multiple myeloma.

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.

Subscribe Now!
Related Videos
5 experts in this video
1 expert is featured in this series.
Magnified bone marrow biopsy showing plasma cells with irregular nuclei and multiple myeloma tumor cells infiltrating normal hematopoietic tissue
5 experts in this video
5 experts in this video
1 expert is featured in this series.
1 expert is featured in this series.
5 experts in this video
5 experts in this video
Related Content
Visualization of CAR T-cells | Image Credit: © furyon - stock.adobe.com
June 9th 2025

Single Infusion of Cilta-Cel Yields 5-Year Progression-Free Survival in Multiple Myeloma

Alexandra Gerlach, Associate Editor
The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma
January 31st 2025

The AQUILA Debate: Daratumumab for Treatment of Smoldering Multiple Myeloma

Alexandra Gerlach, Associate Editor
Visualization of myeloma cells in bone marrow | Image Credit: © Khella - stock.adobe.com
June 1st 2025

MRD Monitoring May Help Redefine Long-Term Goals in Myeloma Therapy

Alexandra Gerlach, Associate Editor
Pharmacy Focus: Oncology Edition
April 17th 2023

Pharmacy Focus: Oncology Edition - Consider Treatment Sequences Carefully in Myeloma

Abnormal myeloma cell growth in bone marrow | Image Credit: © Khella - stock.adobe.com
May 29th 2025

Daratumumab Plus VRd Yields Sustained MRD-Negativity Regardless of Cytogenetic Risk Status in NDMM

Alexandra Gerlach, Associate Editor
Man holding kettlebell handle | Image Credit: © WIrul - stock.adobe.com
May 23rd 2025

Physical Activity Can Improve Quality of Life in Patients With Newly Diagnosed Multiple Myeloma

Alexandra Gerlach, Associate Editor